Kongyi Li

No ORCID on file · 1 paper in corpus
other 2026
Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database
Naunyn-Schmiedeberg's archives of pharmacology ·doi:10.1007/s00210-026-05798-5

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometri…